Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 2, 1998, Pages 263-268

  Boswell, Garry W ^a   Bekersky, Ihor ^a   Buell, Donald ^a   Hiles, Richard ^a,c   Walsh, Thomas J ^b  

^a ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Chrysalis Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX;

ADOLESCENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; HISTOPATHOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; AREA UNDER CURVE; DRUG CARRIERS; FEMALE; LIPOSOMES; MALE; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 0031893392     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Adler-Moore, J. P., and R. T. Proffitt. 1993. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J. Liposome Res. 3:429-450.
2. Anonymous. 1995. Data on file. Fujisawa USA, Inc., Deerfield, Ill.
3. Buler, W. T. 1966. Pharmacology, toxicity, and therapeutic usefulness of amphotericin B. JAMA 195:127-131.
4. Dayan, A. D., and P. K. Working. 1994. Non-clinical studies of the efficacy, pharmacokinetics and safety of amphotericin B colloidal dispersion (ABCD). Round Table Ser. R. Soc. Med. Press 32:12-26.
5. Fielding, R. M. 1991. Liposomal drug delivery. Advantages and limitations from a clinical pharmacokinetic and therapeutic perspective. Clin. Pharmacokinet. 21:155-164.
6. Fielding, R. M., A. W. Singer, L. H. Wang, S. Babbar, and L. S. S. Guo. 1992. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob. Agents Chemother. 36:299-307.
7. Francis, P., L. W. Lee, A. Hoffman, J. Peter, A. Francesconi, J. Bacher, J. Shelhamer, P. Pizzo, and T. J. Walsh. 1994. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. J. Infect. Dis. 169:356-368.
8. Gates, C., and R. J. Pinney. 1993. Amphotericin B and its delivery by liposomal and lipid formulations. J. Clin. Pharm. Ther. 18:147-153.
9. Gorgialis, G. 1991. Overview of liposomes. J. Antimicrob. Ther. 28:39-48.
10. Janknegt, J., S. de Marie, I. A. J. M. Bakker-Woudenberg, and D. J. A. Crommelin. 1992. Liposomal and lipid formulations of amphotericin B. Clin. Pharmacokinet. 23:279-291.
11. Joly, V., F. Dromer, J. Barge, P. Yeni, N. Seta, G. Molas, and C. Carbon. 1989. Incorporation of amphotericin B (AMB) into liposomes alters the AMB-induced acute nephrotoxicity in rabbits. J. Pharm. Exp. Ther. 251:311-316.
12. Lee, J. W., M. A. Amanthea, P. A. Francis, E. E. Navarro, J. Bacher, P. A. Pizzo, and T. J. Walsh. 1994. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob. Agents Chemother. 38:713-718.
13. Longuet, P., V. Joly, P. Amirault, N. Seta, C. Carbon, and P. Yeni. 1991. Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in rats. Antimicrob. Agents Chemother. 35:1303-1308.
14. Lopez-Bernstein, G., R. Meheta, R. L. Hopfer, K. Mills, L. Kasi, K. Meheta, V. Fainstein, M. Luna, E. M. Hersh, and R. Juliano. 1983. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J. Infect. Dis. 147:939-945.
15. MicroMath Scientific Software. 1993. RStrip. Exponential stripping and parameter estimation. MicroMath Scientific Software, Salt Lake City, Utah.
16. Proffitt, R. T., A. Sartorius, S. M. Chiang, L. Sullivan, and J. P. Adler-Moore. 1991. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J. Antimicrob. Chemother. 28(Suppl. B):49-61.
17. van Eaten, E. W. M., M. Otte-Lambillion, W. van Vianen, M. T. ten Kate, and I. A. J. M. Bakker-Woudenberg. 1995. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leukopenic mice infected with Candida albicans. J. Antimicrob. Chemother. 35:509-519.
18. Walsh, T. J., K. Garrett, E. Feuerstein, M. Girton, M. Allende, J. Bacher, A. Francesconi, R. Schaufele, and P. A. Pizzo. 1995. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrob. Agents Chemother. 39:1065-1069.